Target intelligence / Profile preview

Mucus secretions

Molecular classification
Other
01

Overview

"Mucus secretions" refers to the process and product of releasing mucus—a viscoelastic, gel-like layer comprised mainly of mucin glycoproteins—by specialized epithelial cells such as goblet cells and submucosal gland cells in various mucosal tissues (e.g., respiratory tract, gastrointestinal tract, and reproductive tract)[1][3][4]. Mucus functions as a physical barrier, trapping pathogens and particulates, lubricating surfaces, and maintaining hydration and tissue integrity, with composition and secretion tightly regulated by stimuli including calcium signals, neural inputs, and inflammatory mediators[1][2][6]. Abnormalities in mucus secretion and composition are implicated in diseases such as asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and colon cancer[2][4][6]. Mucus secretion is not itself a discrete molecular target, but rather a biological process executed by a range of molecules (especially mucins such as MUC2, MUC5AC, and MUC5B); thus, "Mucus secretions" is not considered a canonical target molecule or receptor for drug development[1][2][6].

Other names
MucusMucus secretionMucus layerMucosal barrier
02

Mechanism of action

Mucolytic action (breakdown of mucus viscosity); Stimulation or inhibition of mucus secretion (e.g., via neural or chemical signaling)

03

Biological functions

Epithelial protectionLubricationPhysical barrier against pathogensInnate immune defenseMucociliary clearanceMaintenance of hydration
04

Disease associations

InflammationInfectionCancer (related to mucosal barrier dysfunction)Gastrointestinal diseases (e.g., inflammatory bowel disease, colorectal cancer)Pulmonary diseases (e.g., asthma, cystic fibrosis, COPD)
05

Safety considerations

Excessive mucus can obstruct airways or digestive passagesMucus depletion increases vulnerability to infections and tissue injuryImbalanced mucus turnover linked to chronic diseases (asthma, IBD, CF)
06

Interacting drugs

N-acetylcysteine

4 more in the full profile.

07

Biomarkers

MUC2, MUC5AC, MUC5B mucin glycoproteins (for mucus production/alteration)Changes in mucus thickness or compositionModified glycan patterns on mucins

Beyond the preview

Go deeper on Mucus secretions.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucus secretions.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call